ReviewEngineering (Beijing, China)2020
Strategies and Advances in Combating COVID-19 in China.
Review in Engineering (Beijing, China), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 25 citations in OpenAlex.
- Epidemiological Trends of COVID-19 Infection and Symptom Incidence in China Following the Adjustment of Zero-COVID Policy: A Prospective, Community-Based Cohort Study.Transboundary and emerging diseases · 2026Article
- PTSD prevalence and factors in intern nursing students after COVID-19 full liberalization in China: a cross-sectional study.Frontiers in public health · 2024Article
- The efficacy of hydrogen/oxygen therapy favored the recovery of omicron SARS-CoV-2 variant infection: results of a multicenter, randomized, controlled trial.Journal of clinical biochemistry and nutrition · 2023Article
- Article
- Reduction in the duration of postoperative fever following NUSS surgery during the COVID-19 pandemic.Italian journal of pediatrics · 2023Article
- Public Health Measures and the Control of COVID-19 in China.Clinical reviews in allergy & immunology · 2023Review
- Quantitative determination of the electron beam radiation dose for SARS-CoV-2 inactivation to decontaminate frozen food packaging.Virologica Sinica · 2022Article
- Alteration of the respiratory microbiome in COVID-19 patients with different severities.Journal of genetics and genomics = Yi chuan xue bao · 2022Article
- Antibacterial mechanism of Cu-bearing 430 ferritic stainless steel.Rare metals · 2022Article
- Discovery of diminazene as a dual inhibitor of SARS-CoV-2 human host proteases TMPRSS2 and furin using cell-based assays.Current research in chemical biology · 2022Article
- Changes in Incidence of Notifiable Infectious Diseases in China Under the Prevention and Control Measures of COVID-19.Frontiers in public health · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronavirus disease 2019 (COVID-19)-the third in a series of coronavirus infections-has caused a global public health event in the 21st century, resulting in substantial global morbidity and mortality. Building on its legacy of managing severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), China has played a key role in the scientific community by revealing the viral transmission routes and clinical characteristics of COVID-19 and developing novel therapeutic interventions and vaccines. Despite these rapid scientific and technological advances, uncertainties remain in tracing the original sources of infection, determining the routes of transmission and pathogenesis, and addressing the lack of targeted clinical management of COVID-19. Here, we summarize the major COVID-19 research advances in China in order to provide useful information for global pandemic control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.